3,5-diaryl-azaindoles as inhibitors of protein DYRK1A for the treatment of cognitive deficiencies related to Down syndrome and Alzheimer's disease

The present invention relates to a compound of formula (I) and salts, solvates and pharmaceutically acceptable hydrates thereof: wherein: 1 to 3 groups of X1-X5 are not a hydrogen atom and the other groups X1-X5 are carbon hydrogen, and 1 to 3 groups of Y1-Y5 are not a hydrogen atom and the other Y1-Y5 groups are hydrogen atoms, and its use as a medicament, especially for the treatment of cognitive disorders related dysfunction Dyrk1A protein.